Effects of Rosuvastatin in combination with Nimodipine in patients with mild cognitive impairment caused by CSVD.
To investigate the clinical efficiency and safeness of the combination of rosuvastatin and nimodipine in treating mild cognitive impairment of CSVD patients. A total of 120 patients with mild cognitive impairment caused by CSVD were divided randomly into two groups: an observation group and a control group, each of which had 60 patients. In the observation group, patients were given rosuvastatin in combination with nimodipine, and other patients were given nimodipine in the control group. For the two groups, the course of treatment was six months. Before and after treatments, levels of TC (total cholesterol), TG (triacylglycerol), LDL-C (low density lipoprotein-cholesterol), HDL-C (high density lipoprotein-cholesterol), MMP-9 and hs-CRP (high sensitivity C reactive protein) were measured. MoCA (Montreal Cognitive Assessment) and ADL (activities of daily living) were also evaluated. Incidence of adverse reactions were compared between two groups. The levels of TG, TC and LDL-C were decreased after treatment in the observation group (P<0.01), and these after-treatment levels were lower than the control group. Additionally, after treatment, the levels of MMP-9 and hs-CRP were significant lower in the observation group than the control group. The MoCA and ADL scores were higher in the observation group than the control group after treatment (P<0.05). Moreover, the overall effective rate were higher in the observation group (91.7%) than the control group (65.0%) (P<0.01), while there was no significant difference of the rate of adverse reactions between the observation group and the control one (10.0% vs. 8.3%) (P>0.05). The combination of rosuvastatin and nimodipine was safe and effective in treating mild cognitive impairment of CSVD patients.